Ren Yamada - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ren Yamada

Showing results (41-50 of 44) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 44 results.

Liver Cancer|June 16, 2023

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab TreatmentShunichi Hosoda, Goki Suda, Takuya Sho, et al.

Journal of Medical Virology|January 4, 2023

Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitisGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.

JHEP Reports : Innovation in Hepatology|April 17, 2025

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCCRisako Kohya, Goki Suda, Masatsugu Ohara, et al.

Hepatology International|August 28, 2025

Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabMasatsugu Ohara, Goki Suda, Risako Kohya, et al.

Pageof 5

Search research articles

Showing results (41-50 of 44) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 44 results.

Liver Cancer|June 16, 2023

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab TreatmentShunichi Hosoda, Goki Suda, Takuya Sho, et al.

Journal of Medical Virology|January 4, 2023

Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitisGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.

JHEP Reports : Innovation in Hepatology|April 17, 2025

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCCRisako Kohya, Goki Suda, Masatsugu Ohara, et al.

Hepatology International|August 28, 2025

Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabMasatsugu Ohara, Goki Suda, Risako Kohya, et al.

Pageof 5